PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination
06 déc. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
OncoResponse Appoints Sean McCarthy to Board of Directors
07 juil. 2021 07h00 HE
|
OncoResponse, Inc.
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to...
OncoResponse Appoints Chris Russell as Chief Financial Officer
11 mai 2021 07h00 HE
|
OncoResponse, Inc.
SEATTLE, May 11, 2021 (GLOBE NEWSWIRE) -- OncoResponse, a biotechnology company harnessing the power of the human immune system to identify and develop novel monoclonal antibodies to...
VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
24 sept. 2018 06h00 HE
|
VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...